Partner with us

Let us help you turn your great ideas into outstanding pharmaceutical formulations. Then take advantage of our large-scale production capabilities to expand your reach.

Partner with Us

What makes Ikigai Corporation Company different?

Ikigai Corporation Company operates in HK SAR, PRC, a region well known for its booming pharmaceutical industry. Many pharmaceutical giants outsource their API manufacturing to this region to make use of the lower production costs possible here. At Ikigai Corporation Company, we have innovative collaborative models that allow us to pool the strengths of our various stakeholders. 

We go beyond temporary sales and single-issue solutions. Our aim at Ikigai Corporation Company is to create win-win partnerships which elevate your brand and offer significant returns on your investments. Partnerships such as the kind we create at Ikigai are also able to respond more effectively to social and environmental challenges.

We work in collaboration, drawing on the unique and diverse abilities of our networks to learn, innovate, and share expertise and knowledge. This approach makes our members effective individually and powerful collectively. We serve our partners by offering our expertise and commit to providing them with the highest quality of service possible. We pride ourselves on our ability to adapt to our business partners, constantly seeking out new ways to fulfil their needs and requirements. 


Partner with Us

Why do our clients choose to work with us?

We get to know our clients’ businesses inside out so that we can provide tailored high-value consultancy. Our consultants are passionate about building productive business relationships based on communication, support, mutual trust, and respect. When our clients work with us, they notice the difference: we care about our external team. 

Our clients are able to access the best talent available when they choose us. By ensuring our team members are motivated and supported, we attract and retain high quality staff. 

We are continually building on our network’s close working relationships through innovations, such as our dedicated Field Managers and Resource teams.

We collaborate with a wide range of organizations in Hong Kong SAR of PRC as well as Mainland PRC, able to make the best use of our global networks through our expertise and built up trust. Our business partners appreciate that we fully understand their corporate social responsibility and marketing strategies. Equally, we appreciate our public and third sector partners’ aims in the areas of development, education, and increased wages.



Partnership benefits

Our partner programs offer a range of benefits for professional fund managers, introducing brokers and affiliates.



Access a wide range of API



Expertise at the service



Booming pharmaceutical industry region




Productive business relationships



Earn at each stage of your business.



Get more clients with the help of our partner specialists.


Why choose Ikigai corporation as your supplier?

Ikigai is a partner you can rely on. We can guarantee the following if your choose us


Quality Products

Quality is our watchword. We only supply quality materials to our customers


Simple Process

No hassles, total transparency and dedicated customer service


Customer commitment

We are constantly seeking out ways to bring more value to our customers


Dynamic services

We are a reputable and influential API supply, marketing and sourcing company


On-going support

With a global presence and strategic partnerships across the globe, you can be sure Ikigai Corporation can support your business anywhere in the world.


Rich expertise

We are specialists in quality assurance, regulatory processes, supply chain and customer service


Cost-effectiveness

By offering competitive prices, we add value to our customer’s products by improving the profitability of their products


Fast delivery

Ikigai will deliver your products in good time to keep your production going.

Our partnership success stories highlight the benefits of partnering with us. Join us?



The Region


Advantages of Operating in Hong Kong SAR PRC

Many investors and entrepreneurs are choosing to set up business in Hong Kong SAR of PRC as they are finding it an easier base to enter international markets from. As part of PRC we enjoy special tax politics and tax-friendly laws and, therefore, can offer you the best prices and competitive conditions. Hong Kong SAR of PRC scores high on a number of factors which are crucial to successful business. These include workforce productivity, infrastructure, location, economic stability, and legal system effectiveness. The city is strategically located for business and offers a very appealing tax regime and business focused, pro-commerce environment.

The Chinese Pharmaceutical Industry  

PRC also has a thriving pharmaceutical industry, which is especially supported by the area’s  stable macroeconomic background. Macroeconomic strength has a direct connection to the industry’s growth rate and success. According to Business PRC, 70% of the market is accounted for by PRC’s thousands of domestic companies, the top 10 companies about 20%.


As a comparison, half of the market is controlled in most developed countries by the top 10 companies. The country’s impressive economic growth has, in large part, been contributed to by the domestic pharmaceutical industry. A professional and in-depth study on the current state of the Pharmaceutical Equipment industry can be found in The PRC Pharmaceutical Equipment Industry 2019 Market Research Report. 

In the PRC’s Pharmaceutical Industry, dynamic features remain steady. PRC implements a program of vertical drug supervision management which augments control over all medicines produced. The government is also setting up a drug management system taking into account best practices, legal management, high efficiency, and standard codes of conduct.

Most of PRC’s pharmaceutical companies manufacture generic drugs. Ikigai Corporation Company specializes in API manufacturing and distribution, a key and source for any finished drug manufacturing.

The Appeal of the Region to Western Corporations
Corporations such as Roche, Pfizer, GlaxoSmithKlein, AstraZeneca, and Novo Nordisk have set up R&D centres and commercial operations in PRC. Other international pharmaceutical companies have started joint ventures in the country. The global pharmaceutical companies present here have achieved full market entry. Many of them are now turning their focus on R&D, which has improved regional supplier and supply chain prospects.

Overseas companies are doing business in PRC mainly to up production while cutting costs. They benefit from less expensive clinical and medical drug trials, lower labour cost, and the vast science and technology research facilities available here. 




Strong Resources

We are a private company, allowing us to provide deeper resources for all your needs.

Strong Resources

We are a private company, allowing us to provide deeper resources for all your needs.


Years of Expertise

We empower you to make quantitative and qualitative decisions

Years of Expertise

We empower you to make quantitative and qualitative decisions




The Industry

Capitalise on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway will close the loop on focusing solely on the bottom line.

Looking at the future of pricing reform, international businesses are increasingly seeing the benefits of outsourcing to keep their profits high. Based in HK SAR, PRC, Ikigai Corporation Company is uniquely positioned to partner with you in growing your business.

Looking to the near future, according to reliable pharmaceutical industry sources, impending pricing reform will lead to even more expanded outsourcing of API and other pharmaceutical components as well as a cost pressure. A continued emphasis on reducing medication prices may compromise traditional pricing models in this case. It is likely that the U.S. Congress will drive reform of pricing models. This will have an impact on drug development and possibly accelerate the release of biosimilar and generic pharmaceutical versions, of which Ikigai Corporation Company is a reputable and established supplier.

In an effort to keep their profits high, industry experts are expecting pharmaceutical companies to continue expanding the use of outsourced companies in an effort to reduce expenses. As is the current situation, most of the important pharmaceutical distribution operations will continue to be outsourced by leading American and European manufacturers to Asian countries such as PRC. Ikigai Corporation Company is uniquely positioned for outsourcing as a partner and ally that is not only a supplier of APIs but is also set up to take responsibility for logistics and packaging. Profit-conscious international pharmaceutical corporations are able to turn to us for support and to access our best-in-class capabilities.

The global API market is sectioned off into groups based on the type of business, therapeutic application, synthesis, and geographic location. The category of synthesis is segmented further into biotech API, synthetic API, and highly potent API. In 2018, it was synthetic API which held the biggest share and it is projected to continue experiencing consistent growth every year until 2035.

The primary business income of PRC’s API manufacturing is currently equivalent to USD 72.1 billion in local currency with an annual growth rate of approx. 15%. This is a significant increase. Our PRC’s manufacturing partners reflect this advancing trend of shifting the level from merely a big industry player to global power. API’s export has now reached USD 29.1 billion and is growing by approx. 14% per annum.



Asia’s pharmaceutical industry has taken another leap forward, increasing in size even in the current environment of pharmaceutical supply reforms and economic adjustments being experienced globally. Why has this been the case? The answer can be seen in the ratio of imported to exported high-value biochemical drug products, which continues to increase in the western hemisphere. These indicators of unlimited potential, coupled with the steadily advancing achievements being seen, show that PRC’s pharmaceutical industry is leading the way to development that is both healthy and sustainable.

This fact is reflected in the statistics and hard figures coming out of the US. According to data from the U.S. Congress, it can be seen that as much as 80% of APIs in the U.S. are actually produced in other countries. The vast majority of these APIs enter the U.S. from PRC and India. Interestingly, a large number of the APIs coming from India are made in PRC.

Ikigai Corporation Company is well-attuned to sector developments and our aim is to provide a significant return for our shareholders. This is achieved by acquiring and managing a portfolio that includes: companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries.

Our Hong Kong SAR, PRC company’s leadership extends to API, mediation, and organic and industrial chemicals and is the outcome of our consistent focus and attention to innovation. We serve our clients’ needs and requirements, maintaining our high customer-focused philosophy, and  keeping this focus on our trademark. We have an in-depth, unbiased insight into the regional pharmaceutical industry, which our clients benefit from, and we source and supply APIs based on that knowledge. Our experienced and capable team is able to meet our customer’s demands within any preset period of time.


Tailored collaborations

Coverage and commitment throughout the entire pharmaceutical value chain

Tailored collaborations

Coverage and commitment throughout the entire pharmaceutical value chain


LOCATIONS

Our network




GET IN TOUCH

Follow us